SA
Sign upLog In
← Back to the wire

Protalix BioTherapeutics Reports Q2 2026 Financial Results with Revenue of $5.2 Million

Earnings·2 articles across 2 outlets·◆ Primary source

Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data

PLX

Protalix BioTherapeutics reported its financial results for the second quarter of 2026, revealing total revenue of $5.2 million. The company highlighted its ongoing commitment to advancing its pipeline and business operations.

During the earnings call, Protalix emphasized its strategic initiatives and future outlook, aiming to enhance shareholder value and drive growth in the coming quarters.

Protalix BioTherapeutics

Sources

Every quote below is verbatim from the article it is attributed to.

SourceReports the news
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.